Additional to targeting IL-6 receptor with tocilizumab, sirukumab (IL-6 neutralization) and inhibition of the Janus kinase–signal transducers and activators of transcription (JAK–STAT) pathway [2] are being investigated as possible treatment options to resolve inflammation in GCA patients. This evidence concerns the gene IL6 and temporal arteritis.